Viral rebound common in lung transplant recipients treated with nirmatrelvir/ritonavir for COVID-19 Post author: Post published:October 24, 2023 Post category:uncategorized Data on the viral rebound and safety of nirmatrelvir/ritonavir in lung transplant (LTx) recipients are limited. You Might Also Like Long-term physical activity can prevent obesity-induced cognitive decline November 30, 2023 Cultivating strength: How yogurt boosts skeletal muscle health October 16, 2023 Expanded use of common antibiotic cuts child mortality by 14% in Sub-Saharan Africa August 21, 2024